Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHMI evaluation of ProC6C-AlOH/Matrix-M malaria vaccine in healthy Malian adults
PACTR202404598604620Phase 2Unknown
- Sponsor
- Université des Sciences, des Techniques et des Technologies de Bamako
- Start
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of rabies virus inactivated antigen, A in malaria (2 arms), sponsored by Université des Sciences, des Techniques et des Technologies de Bamako. Primary endpoints: Time to patent parasitemia after CHMI and Adverse events. Status: unknown.
02
Drugs
rabies virus inactivated antigen, A
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202404598604620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202404598604620.